Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2018 | Pages:
110 | Publisher: Grand View Research
Industry: Healthcare | Report Format: Electronic (PDF)
The North America Molecular Diagnostics (MDx) market size is expected to reach USD 8.10 billion by 2025 expanding at a CAGR of 10.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of long-term diseases, such as cancer, Cardiovascular Diseases (CVDs), neurological disorders, obesity, and diabetes, is expected to drive the North America MDx market. According to the Population Reference Bureau, in U.S., the number of people aged 65 years and older is estimated to increase from 46 million in 2016 to around 98 million by 2060. Moreover, the data published by WHO states that the life expectancy is now exceeding to 80 years in most of the developed countries in the region. Thus, growing geriatric population is also likely to augment the market development. Aging characterizes the single most substantial risk factor for cancer development. Based on the U.S. National Cancer Institute's Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in individuals above the age of 65 years. This is where molecular diagnostics plays an important role as it has a tremendous impact on the management of suffering from chronic diseases such as cancer and Cardiovascular Diseases (CVDs). It is also vital for public health surveillance and detection. Growing need for easy access to MDx has driven the Point-of-Care (PoC) market. One of the advantages offered by molecular diagnostics is that it can detect a disease even before the patient becomes symptomatic. PoC devices offer fast results, which, in turn, helps start treatments before the disease grows. With respect to infectious disease, early diagnosis can reduce pain, recovery time, and stop or slower the spread of disease. Further key findings from the study suggest: • Reagents led the North America molecular diagnostics market in 2017 owing to high number of R&D activities pertaining to self-test and PoC products • Central laboratories held the largest revenue share in 2017 due to factors, such as availability of skilled labor and well-established infrastructure • PoC segment is estimated to witness lucrative growth over the forecast period owing to rising healthcare awareness and demand for bedside testing • Infectious diseases segment was the largest application segment in 2017 owing to increased cases of tuberculosis, pneumonia, HIV, and others • Oncology segment is estimated to witness the fastest growth during the forecast period as it involves a number of diseases with unmet clinical needs for improved therapeutics and diagnostics • Key companies are Roche Diagnostics; Qiagen N.V.; Danaher Corp.; Hologic, Inc; Johnson & Johnson; Becton, Dickinson and Company; Abbott Laboratories; bioMerieux SA; Illumina, Inc.; Novartis AG; and Cepheid, Inc.
Table of Contents
Chapter 1 Research Methodology & Scope
1.1 Information procurement
1.1.1 Purchased database:
1.1.2 GVR's Internal Database
1.2 Research Methodology
1.3 Geographic Scope & Assumptions
1.4 North America Market Calculation
1.4.1 North America Market: Base estimates
1.4.2 North America Market: CAGR calculation
1.5 Segment Share Calculation
1.6 Primary Sources
1.7 List of Secondary Sources
Chapter 2 Executive Summary
2.1 Market Snapshot
Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation& scope
3.1.1 Market Driver Analysis
3.1.1.1 Growing geriatric population base
3.1.1.2 Introduction of technologically advanced products
3.1.1.3 Increase in demand for point-of-care facilities
3.1.1.4 Growing prevalence of target diseases such as genetic, cardiovascular, and neurological diseases and hospital-acquired infections
3.1.1.5 Increasing external funding for R&D
3.1.2 Market Restraint Analysis
3.1.2.1 Presence of ambiguous regulatory framework
3.1.2.2 High prices of molecular diagnostics tests
3.2 Penetration & growth prospect mapping
3.3 North America Molecular Diagnostics - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter's
Chapter 4 North America MDx Market: Product Estimates & Trend Analysis
4.1 North America Molecular diagnostics market: Product movement analysis
4.2 Instruments
4.2.1 Instruments market, 2014 - 2025 (USD Million)
4.3 Reagents
4.3.1 Reagents market, 2014 - 2025 (USD Million)
4.4 Others
4.4.1 Others market, 2014 - 2025 (USD Million)
Chapter 5 North America MDx Market: Test Location Estimates & Trend Analysis
5.1 North America Molecular diagnostics market: Test Location movement analysis
5.2 Point of Care (PoC)
5.2.1 PoC market, 2014 - 2025 (USD Million)
5.3 Self-test or Over the Counter (OTC)
5.3.1 Self-test or OTC market, 2014 - 2025 (USD Million)
5.4 Central laboratories
5.4.1 Central laboratories market, 2014 - 2025 (USD Million)
Chapter 6 North America MDx Market: Technology Estimates & Trend Analysis
6.1 North America Molecular diagnostics market: Technology movement analysis
6.2 Polymerase Chain Reaction (PCR)
6.2.1 PCR market, 2014 - 2025 (USD Million)
6.2.2 Multiplex PCR
6.2.2.1 Multiplex PCR market, 2014 - 2025 (USD Million)
6.2.3 Other PCR
6.2.3.1 Other PCR market, 2014 - 2025 (USD Million)
6.3 In Situ Hybridization
6.3.1 In Situ Hybridization market, 2014 - 2025 (USD Million)
6.4 Isothermal Nucleic Acid Amplification Technology (INAAT)
6.4.1 INAAT market, 2014 - 2025 (USD Million)
6.5 Chips and microarrays
6.5.1 Chips and microarrays market, 2014 - 2025 (USD Million)
6.6 Mass spectrometry
6.6.1 Mass spectrometry market, 2014 - 2025 (USD Million)
6.7 Sequencing
6.7.1 Sequencing market, 2014 - 2025 (USD Million)
6.8 Transcription Mediated Amplification (TMA)
6.8.1 TMA market, 2014 - 2025 (USD Million)
6.9 Others
6.9.1 Other market, 2014 - 2025 (USD Million)
Chapter 7 North America MDx Market: Application Estimates & Trend Analysis
7.1 North America Molecular diagnostics market: Application movement analysis
7.2 Oncology
7.2.1 Oncology market, 2014 - 2025 (USD Million)
7.2.2 Breast Cancer
7.2.2.1 Breast Cancer market, 2014 - 2025 (USD Million)
7.2.3 Prostate Cancer
7.2.3.1 Prostate Cancer market, 2014 - 2025 (USD Million)
7.2.4 Colorectal Cancer
7.2.4.1 Colorectal Cancer market, 2014 - 2025 (USD Million)
7.2.5 Cervical Cancer
7.2.5.1 Cervical cancer market, 2014 - 2025 (USD Million)
7.2.6 Kidney Cancer
7.2.6.1 Kidney cancer market, 2014 - 2025 (USD Million)
7.2.7 Liver Cancer
7.2.7.1 Liver cancer market, 2014 - 2025 (USD Million)
7.2.8 Blood Cancer
7.2.8.1 Blood cancer market, 2014 - 2025 (USD Million)
7.2.9 Lung Cancer
7.2.9.1 Lung cancer market, 2014 - 2025 (USD Million)
7.2.10 Other cancer
7.2.10.1 Other cancer market, 2014 - 2025 (USD Million)
7.3 Pharmacogenomics
7.3.1 Pharmacogenomics market, 2014 - 2025 (USD Million)
7.4 Infectious diseases
7.4.1 Infectious diseases market, 2014 - 2025 (USD Million)
7.4.2 Methicillin-resistant Staphylococcus Aureus (MRSA)
7.4.2.1 Methicillin-resistant Staphylococcus Aureus (MRSA) market, 2014 - 2025 (USD Million)
7.4.3 Clostridium difficile
7.4.3.1 Clostridium difficile market, 2014 - 2025 (USD Million)
7.4.4 Vancomycin-resistant Enterococci (VRE)
7.4.4.1 Vancomycin-resistant enterococci market, 2014 - 2025 (USD Million)
7.4.5 Carbapenem-resistant bacteria
7.4.5.1 Carbapenem-resistant bacteria market, 2014 - 2025 (USD Million)
7.4.6 Flu
7.4.6.1 Flu market, 2014 - 2025 (USD Million)
7.4.7 Respiratory Syncytial Virus (RSV)
7.4.7.1 Respiratory Syncytial Virus (RSV) market, 2014 - 2025 (USD Million)
7.4.8 Candida
7.4.8.1 Candida market, 2014 - 2025 (USD Million)
7.4.9 Tuberculosis and drug-resistant TBA
7.4.9.1 Tuberculosis and Drug-resistant TBA market, 2014 - 2025 (USD Million)
7.4.10 Meningitis market
7.4.10.1 Meningitis market, 2014 - 2025 (USD Million)
7.4.11 Gastrointestinal Panel Testing
7.4.11.1 Gastrointestinal panel testing market, 2014 - 2025 (USD Million)
7.4.12 Chlamydia
7.4.12.1 Chlamydia market, 2014 - 2025 (USD Million)
7.4.13 Gonorrhea
7.4.13.1 Gonorrhea market, 2014 - 2025 (USD Million)
7.4.14 HIV
7.4.14.1 HIV market, 2014 - 2025 (USD Million)
7.4.15 Hepatitis C
7.4.15.1 Hepatitis C market, 2014 - 2025 (USD Million)
7.4.16 Hepatitis B
7.4.16.1 Hepatitis B market, 2014 - 2025 (USD Million)
7.4.17 Other Infectious disease market
7.4.17.1 Other infectious disease market, 2014 - 2025 (USD Million)
7.5 Genetic Testing
7.5.1 Genetic testing market, 2014 - 2025 (USD Million)
7.5.2 Newborn Screening
7.5.2.1 Newborn screening market, 2014 - 2025 (USD Million)
7.5.3 Predictive and Presymptomatic Testing
7.5.3.1 Predictive and presymptomatic testing market, 2014 - 2025 (USD Million)
7.5.4 Other Genetic Testing
7.5.4.1 Other genetic testing market, 2014 - 2025 (USD Million)
7.6 Neurological Diseases
7.6.1 Neurological diseases market, 2014 - 2025 (USD Million)
7.7 Cardiovascular Disease
7.7.1 Cardiovascular disease market, 2014 - 2025 (USD Million)
7.8 Microbiology
7.8.1 Microbiology market, 2014 - 2025 (USD Million)
7.9 Others
7.9.1 Others market, 2014 - 2025 (USD Million)
Chapter 8 North America Molecular diagnostics market: Geographic Analysis
8.1 North America
8.1.1 North America molecular diagnostics market, 2014 - 2025 (USD Million)
8.1.2 U.S.
8.1.2.1 U.S. molecular diagnostics market, 2014 - 2025 (USD Million)
8.1.3 Canada
8.1.3.1 Canada molecular diagnostics market, 2014 - 2025 (USD Million)
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Market Share Analysis
9.4 Company Profile
9.4.1 Roche Diagnostics
9.4.1.1 Company overview
9.4.1.2 Financial performance
9.4.1.3 Product benchmarking
9.4.1.4 Strategic initiatives
9.4.2 Abbott
9.4.2.1 Company overview
9.4.2.2 Alere, Inc.
9.4.2.3 Financial performance
9.4.2.4 Product benchmarking
9.4.2.5 Strategic initiatives
9.4.3 Becton, Dickinson and Company
9.4.3.1 Company overview
9.4.3.2 Financial performance
9.4.3.3 Product benchmarking
9.4.3.4 Strategic initiatives
9.4.4 bioMérieux SA
9.4.4.1 Company overview
9.4.4.2 Financial performance
9.4.4.3 Product benchmarking
9.4.4.4 Strategic initiatives
9.4.5 Bio-Rad Laboratories, Inc.
9.4.5.1 Company overview
9.4.5.2 Financial performance
9.4.5.3 Product benchmarking
9.4.5.4 Strategic initiatives
9.4.6 Dako
9.4.6.1 Company overview
9.4.6.2 Financial performance
9.4.6.3 Product benchmarking
9.4.6.4 Strategic initiatives
9.4.7 Danaher Corporation
9.4.7.1 Company overview
9.4.7.2 Cepheid
9.4.7.3 Beckman Coulter
9.4.7.4 Leica Biosystems
9.4.7.5 Financial performance
9.4.7.6 Product benchmarking
9.4.7.7 Strategic initiatives
9.4.7.8 Strategic initiatives of Cepheid
9.4.7.9 Strategic initiatives of Beckman Coulter, Inc.
9.4.7.10 Strategic initiatives of Leica Biosystems
9.4.8 Hologic, Inc. (Gen Probe)
9.4.8.1 Company overview
9.4.8.2 Financial performance
9.4.8.3 Product benchmarking
9.4.8.4 Strategic initiatives
9.4.9 Illumina, Inc.
9.4.9.1 Company overview
9.4.9.2 Financial performance
9.4.9.3 Product benchmarking
9.4.9.4 Strategic initiatives
9.4.10 Johnson & Johnson Services, Inc.
9.4.10.1 Company overview
9.4.10.2 Financial performance
9.4.10.3 Product benchmarking
9.4.10.4 Strategic initiatives
9.4.11 Novartis (Grifols)
9.4.11.1 Company overview
9.4.11.2 Financial performance
9.4.11.3 Product benchmarking
9.4.11.4 Strategic initiatives
9.4.12 Qiagen
9.4.12.1 Company overview
9.4.12.2 Financial performance
9.4.12.3 Product benchmarking
9.4.12.4 Strategic initiatives
9.4.13 Siemens Healthcare Private Limited
9.4.13.1 Company overview
9.4.13.2 Financial performance
9.4.13.3 Product benchmarking
9.4.13.4 Strategic initiatives
9.4.14 Sysmex Corporation
9.4.14.1 Company overview
9.4.14.2 Financial performance
9.4.14.3 Product benchmarking
9.4.14.4 Strategic initiatives
List of Tables TABLE 1 North America molecular diagnostics market estimates and forecasts, by product, 2014 - 2025 (USD Million) TABLE 2 North America molecular diagnostics market estimates and forecasts, by test location, 2014 - 2025 (USD Million) TABLE 3 North America molecular diagnostics market estimates and forecasts, by technology, 2014 - 2025 (USD Million) TABLE 4 North America molecular diagnostics market estimates and forecasts, by application, 2014 - 2025 (USD Million) TABLE 5 U.S. molecular diagnostics market estimates and forecasts, by product, 2014 - 2025 (USD Million) TABLE 6 U.S. molecular diagnostics market estimates and forecasts, by test location, 2014 - 2025 (USD Million) TABLE 7 U.S. molecular diagnostics market estimates and forecasts, by technology, 2014 - 2025 (USD Million) TABLE 8 U.S. molecular diagnostics market estimates and forecasts, application, 2014 - 2025 (USD Million) TABLE 9 Canada molecular diagnostics market estimates and forecasts, by product, 2014 - 2025 (USD Million) TABLE 10 Canada molecular diagnostics market estimates and forecasts, by test location, 2014 - 2025 (USD Million) TABLE 11 Canada molecular diagnostics market estimates and forecasts, by technology, 2014 - 2025 (USD Million) TABLE 12 Canada molecular diagnostics market estimates and forecasts, by application, 2014 - 2025 (USD Million)
List of Figures FIG. 1 Market research process FIG. 2 Information procurement FIG. 3 Market summary, 2017 FIG. 4 Market trends & outlook FIG. 5 Market segmentation & scope FIG. 6 Market driver relevance analysis (Current & future impact) FIG. 7 General trend shifts from laboratory to Point of Care FIG. 8 Market restrain relevance analysis (Current & future impact) FIG. 9 Average selling price range of diagnostic tests, 2017 FIG. 10 Penetration & growth prospect mapping FIG. 11 SWOT analysis, by factor (political & legal, economic and technological) FIG. 12 Porter's five forces analysis FIG. 13 Molecular diagnostics market product outlook key takeaways FIG. 14 North America Molecular diagnostics market: Product movement analysis FIG. 15 North America instruments market, 2014 - 2025 (USD Million) FIG. 16 North America reagents market, 2014 - 2025 (USD Million) FIG. 17 North America others market, 2014 - 2025 (USD Million) FIG. 18 North America Molecular diagnostics market test location outlook: Key takeaways FIG. 19 North America Molecular diagnostics market: Test location movement analysis FIG. 20 North America PoC market, 2014 - 2025 (USD Million) FIG. 21 North America self-test or OTC market, 2014 - 2025 (USD Million) FIG. 22 North America central laboratories market, 2014 - 2025 (USD Million) FIG. 23 North America Molecular diagnostics market technology outlook: Key takeaways FIG. 24 North America Molecular diagnostics market: Technology movement analysis FIG. 25 North America PCR market, 2014 - 2025 (USD Million) FIG. 26 North America multiplex PCR market, 2014 - 2025 (USD Million) FIG. 27 North America other PCR market, 2014 - 2025 (USD Million) FIG. 28 North America in situ hybridization market, 2014 - 2025 (USD Million) FIG. 29 North America INAAT market, 2014 - 2025 (USD Million) FIG. 30 North America chips and microarrays market, 2014 - 2025 (USD Million) FIG. 31 North America mass spectrometry market, 2014 - 2025 (USD Million) FIG. 32 North America sequencing market, 2014 - 2025 (USD Million) FIG. 33 North America TMA market, 2014 - 2025 (USD Million) FIG. 34 North America other market, 2014 - 2025 (USD Million) FIG. 35 North America Molecular diagnostics market application outlook: Key takeaways FIG. 36 North America Molecular diagnostics market: Application movement analysis FIG. 37 North America oncology market, 2014 - 2025 (USD Million) FIG. 38 North America breast cancer market, 2014 - 2025 (USD Million) FIG. 39 North America prostate cancer market, 2014 - 2025 (USD Million) FIG. 40 North America colorectal cancer market, 2014 - 2025 (USD Million) FIG. 41 North America cervical cancer market, 2014 - 2025 (USD Million) FIG. 42 North America kidney cancer market, 2014 - 2025 (USD Million) FIG. 43 North America Liver Cancer market, 2014 - 2025 (USD Million) FIG. 44 North America blood cancer market, 2014 - 2025 (USD Million) FIG. 45 North America lung cancer market, 2014 - 2025 (USD Million) FIG. 46 North America other market, 2014 - 2025 (USD Million) FIG. 47 North America pharmacogenomics market, 2014 - 2025 (USD Million) FIG. 48 North America infectious disease market, 2014 - 2025 (USD Million) FIG. 49 North America MRSA market, 2014 - 2025 (USD Million) FIG. 50 North America clostridium difficile market, 2014 - 2025 (USD Million) FIG. 51 North America vancomycin-resistant enterococci market, 2014 - 2025 (USD Million) FIG. 52 North America carbapenem-resistant bacteria market, 2014 - 2025 (USD Million) FIG. 53 North America flu market, 2014 - 2025 (USD Million) FIG. 54 North America RSV market, 2014 - 2025 (USD Million) FIG. 55 North America candida market, 2014 - 2025 (USD Million) FIG. 56 North America tuberculosis and drug-resistant TB market, 2014 - 2025 (USD Million) FIG. 57 North America meningitis market, 2014 - 2025 (USD Million) FIG. 58 North America gastro-intestinal panel market, 2014 - 2025 (USD Million) FIG. 59 North America chlamydia market, 2014 - 2025 (USD Million) FIG. 60 North America gonorrhoea market, 2014 - 2025 (USD Million) FIG. 61 North America HIV market, 2014 - 2025 (USD Million) FIG. 62 North America hepatitis C market, 2014 - 2025 (USD Million) FIG. 63 North America Hepatitis B market, 2014 - 2025 (USD Million) FIG. 64 North America market for others, 2014 - 2025 (USD Million) FIG. 65 North America genetic testing market, 2014 - 2025 (USD Million) FIG. 66 North America newborn screening market, 2014 - 2025 (USD Million) FIG. 67 North America predictive and presymptomatic testing market, 2014 - 2025 (USD Million) FIG. 68 North America other market, 2014 - 2025 (USD Million) FIG. 69 North America neurological disease market, 2014 - 2025 (USD Million) FIG. 70 North America cardiovascular disease market, 2014 - 2025 (USD Million) FIG. 71 North America microbiology market, 2014 - 2025 (USD Million) FIG. 72 North America other technology market, 2014 - 2025 (USD Million) FIG. 73 North America molecular diagnostics market, 2014 - 2025 (USD Million) FIG. 74 U.S. molecular diagnostics market, 2014 - 2025 (USD Million) FIG. 75 Canada molecular diagnostics market, 2014 - 2025 (USD Million) FIG. 76 Strategy framework FIG. 77 Participant categorization FIG. 78 Company Market Share Analysis -Molecular diagnostics Market, 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
